ERBB2 and cancer: In addition, we also selected 501 patients from METABRIC whose breast cancer receptor status matched the patients in our imaged cohort (ER−PR−HER2− = 320 patients; ER−PR−HER2+ = 134 patients; ER+PR+HER2+ = 47 patients).